Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 1627 • ACR Convergence 2025
A systematic literature review to inform the 2025 EULAR recommendations for management of Polymyalgia Rheumatica and Large Vessel Vasculitis: management of disease including relapse and complications
Mrinalini Dey¹, Durga Prasanna Misra², Alice Bartoletti³, Georgina Ducker⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ³ASST Gaetano Pini CTO, Cremona, Italy, ⁴Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: EULAR recommendations informing the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) were previously published separately in 2015 [1] and 2020 [2]…
Abstract Number: 0734 • ACR Convergence 2025
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
Julie Mouchet¹, Lauren Revie², Tim Nguyen³, Liwei Zhao⁴, Valeria Jordan M.⁵, G S Ramakrishna⁶, Linda Grinnell-Merrick³, Atif Adam⁷ and Minouk Schoemaker⁸, ¹Novartis Pharma AG, Basel, Switzerland, ²IQVIA, EMEA, London, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴IQVIA, Real World Solutions, Mölndal, Sweden, ⁵Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷IQVIA Inc, Boston, ⁸IQVIA, Real World Solutions, Amsterdam, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…
Abstract Number: 1619 • ACR Convergence 2025
Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
Gaston Ariel Ghio¹, Maria Gabriela Paz Machado², Evelin Encalada², Imma Perez Nadales², Georgina Salvador Alarcón², Elena Riera Alonso², manel pujol², Marta Pujol Teixidor² and Silvia Martinez Pardo², ¹Hospital Universitari Mùtua Terrassa, Terrassa, Catalonia, Spain, ²Hospital Universitari Mùtua Terrassa, Terrassa, Spain
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are chronic inflammatory disorders predominantly affecting patients over 50. Despite unclear etiopathogenesis, both conditions share central…
Abstract Number: 0349 • ACR Convergence 2025
Underrecognized Glucocorticoid-Induced Osteoporosis in a Polymyalgia Rheumatica Patient Cohort
katherine Loomba¹, Emily Campbell¹, Nisha Khubchandani¹, chih Fang¹, William Rigby² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
Abstract Number: 1617 • ACR Convergence 2025
Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
Erik Stone¹, Shilpa Venkatachalam², angela Degrassi³, Laura Stradford¹, Ambika Vartak⁴ and Shelley Fritz⁵, ¹Global Healthy Living Foundation, Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Meriden, ⁵Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Polymyalgia rheumatica (PMR) is a commonly occurring inflammatory condition affecting older adults, primarily presenting with bilateral shoulder and hip stiffness. Despite its high prevalence…
Abstract Number: 1616 • ACR Convergence 2025
Short-Course Prednisone and Methotrexate in Polymyalgia Rheumatica: A Potential Therapeutic Approach
Edoardo Conticini¹, Silvia Grazzini¹, Raffaele Truscelli², Paolo Falsetti³, Luca Cantarini⁴ and Bruno Frediani⁴, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²University of Siena, Siena, Italy, ³Siena University Hospital, Siena, Italy, ⁴Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Despite being considered an easy-to-diagnose and easy-to-treat condition, the optimal treatment of PMR is far from being fully elucidated. Three recently published trials have…
Abstract Number: 1614 • ACR Convergence 2025
A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
Alice Bartoletti¹, Georgina Ducker², Mrinalini Dey³, Durga Prasanna Misra⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Department of Rheumatology, ASST Gaetano Pini CTO, Milan, Italy, Milan, Lombardia, Italy, ²Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ³Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK, London, England, United Kingdom, ⁴Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) date back to 2015…
Abstract Number: 1175 • ACR Convergence 2025
Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Juergen Rech⁴, Leonore Unger⁵, Stephanie Finzel⁶, Ioana Andreica⁷, David Kofler⁸, Stefan Weiner⁹, Prof. Dr. med. Peter Lamprecht¹⁰, Hendrik Schulze-Koops¹¹, Meryl Mendelson¹², Weibin Bao¹³, Monica Keyport¹⁴, Meron Maricos¹⁵, Valeria Jordan M.¹⁶ and Jens Thiel¹⁷, ¹University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ³Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵Städtisches Klinikum Dresden, Dresden, Germany, ⁶Universitétsklinikum Freiburg, Freiburg im Breisgau, Germany, ⁷Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Brüderkrankenhaus Trier, Trier, Germany, ¹⁰University of Lübeck, Lübeck, Germany, ¹¹LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ¹²Novartis Pharmaceuticals, Larchmont, NY, ¹³Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁴Novartis Pharmaceuticals, Stillwater, MN, ¹⁵Novartis, Nürnberg, Germany, ¹⁶Novartis Pharmaceuticals Corporation, Tenafly, NJ, ¹⁷University Hospital Freiburg, Medical University Graz, Freiburg, Germany
Background/Purpose: GCA and PMR are closely related, immune-mediated chronic inflammatory diseases often occurring concurrently in individuals over 50.1,2 While glucocorticoids (GC) are the mainstay of…
Abstract Number: 1150 • ACR Convergence 2025
Impact of IL-17A on synovial fibroblast from subacromial bursae
Andre Ramon¹, Hélène Greigert², baptiste lamarthée³, Corentin Richard⁴, claudie Cladière³, Noemie Klopfenstein³, Ludovic Labattut⁵, Alice Bordet⁵, Sylvain Audia⁶, Romain boidot⁴, jean-francis Maillefert¹, Bernard Bonnotte⁷ and Maxime Samson⁸, ¹Rheumatology, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ²Vascular Medicine, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ³Marie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, Besançon, France, Dijon, France, ⁴Molecular Biology Unit, Georges-François Leclerc Cancer Center, UNICANCER, Dijon, France, Dijon, France, ⁵Orthopedic Surgery, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ⁶Internal Medicine and Clinical Immunology, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ⁷Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, ⁸CHU Dijon Bourgogne, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by increases in serum IL-6 and the proportion of Th17 cells in circulating blood. During PMR, IL-6 may originate…
Abstract Number: 1102 • ACR Convergence 2025
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Julia Barasch¹, Nilasha Ghosh², Deanna Jannat-Khah³, Kyle Ge⁴, Jeffrey Curtis⁵ and Anne R. Bass³, ¹NYP- Weill Cornell, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 1238 • ACR Convergence 2024
Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², seoidin McKittrick³, Robert Harrington⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland, ⁴St. James's Hospital, Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: One of the most significant unmet needs in the management of those with Polymyalgia Rheumatica (PMR) is the lack of a disease stratification tool…
Abstract Number: 2513 • ACR Convergence 2024
Frequency, Diagnosis, and Management of Polymyalgia Rheumatica in Germany – Database Analysis of Medical Insurance Data
Wolfgang Schmidt¹, Marco Alibone², Paul Ludwig², Dominik Obermüller², Dennis Häckl³, Katrin Tönnessen⁴, Mirjam Fließer⁴, Franziska Karl⁴, Hien Nguyen⁴, Annika Boas⁴ and Nils Venhoff⁵, ¹Immanuel Krankenhaus Berlin, Berlin, Germany, ²InGef-Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ³WIG2 GmbH, Leipzig, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany
Background/Purpose: To date, there is limited data on the epidemiology of polymyalgia rheumatica (PMR) in Germany. National prevalence estimates suggest only 69,000 affected individuals, which…
Abstract Number: 0739 • ACR Convergence 2024
One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic
Patricia Harkins¹, Sharon Cowley², Robert Harrington³, seoidin McKittrick⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³St. James's Hospital, Dublin, Dublin, Ireland, ⁴University of Limerick, Limerick, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: To date the longitudinal outcomes of those with isolated Polymyalgia Rheumatica (PMR) are poorly understood, owing largely to the fact that in the majority…
Abstract Number: 1318 • ACR Convergence 2024
Patient Anxiety, Fear, and Kinesiophobia: Challenges Shared by UK Physiotherapists in Managing Polymyalgia Rheumatica – Findings from a Qualitative Study
Anne O'Brien¹, Sara Muller¹, Jennifer Liddle², Martin Thomas¹ and Christian D Mallen³, ¹Keele University, Keele, Staffordshire, England, United Kingdom, ²Newcastle University, Newcastle upon Tyne, United Kingdom, ³Keele University, Keele, Staffordshire, United Kingdom
Background/Purpose: Polymyalgia Rheumatica (PMR) is the commonest rheumatic condition affecting older people. 35% of newly diagnosed patients report anxiety, (Muller et al., 2016) which, with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].